| Trial ID: | L4255 |
| Source ID: | NCT02754817
|
| Associated Drug: |
Insulin Degludec/Liraglutide
|
| Title: |
A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: insulin degludec/liraglutide
|
| Outcome Measures: |
Primary: Change in HbA1c (Hemoglobin A1c), week 0, week 26 | Secondary: Change in HbA1c, Month 0, month 3, month 9, months 12|Percentage of responders for HbA1c below 7 percent (53 mmol/mol), At 3, 6, 9 and 12 months|Percentage of responders for HbA1c below 7 percent (53 mmol/mol) with no weight gain, At 3, 6, 9 and 12 months|Percentage of responders for HbA1c below 7 percent (53 mmol/mol) with no hypoglycaemic episodes, At 3, 6, 9 and 12 months
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
611
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2016-04-26
|
| Completion Date: |
2016-10-20
|
| Results First Posted: |
|
| Last Update Posted: |
2018-01-12
|
| Locations: |
Novo Nordisk Investigational Site, Wien, 1130, Austria|Novo Nordisk Investigational Site, Leipzig, 04103, Germany|Novo Nordisk Investigational Site, Stockholm, 111 57, Sweden|Novo Nordisk Investigational Site, St. Gallen, 9016, Switzerland|Novo Nordisk Investigational Site, Stevenage, SG1 4AB, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT02754817
|
